[go: up one dir, main page]

WO2000069404A1 - Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions - Google Patents

Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions Download PDF

Info

Publication number
WO2000069404A1
WO2000069404A1 PCT/US2000/012155 US0012155W WO0069404A1 WO 2000069404 A1 WO2000069404 A1 WO 2000069404A1 US 0012155 W US0012155 W US 0012155W WO 0069404 A1 WO0069404 A1 WO 0069404A1
Authority
WO
WIPO (PCT)
Prior art keywords
safe
effective amount
skin
composition
skm
Prior art date
Application number
PCT/US2000/012155
Other languages
English (en)
French (fr)
Inventor
John Chengfeng Zhuang
John Erich Oblong
Donald Lynn Bissett
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to EP00928813A priority Critical patent/EP1181006A1/en
Priority to CA002373158A priority patent/CA2373158A1/en
Priority to AU46992/00A priority patent/AU771934B2/en
Priority to BR0010619-4A priority patent/BR0010619A/pt
Priority to JP2000617863A priority patent/JP2002544217A/ja
Priority to MXPA01011801A priority patent/MXPA01011801A/es
Publication of WO2000069404A1 publication Critical patent/WO2000069404A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to methods of regulating the condition of mammalian keratinous tissue using defined phytosterols wherein the methods include, a) thickening skin and preventmg, retarding, and/or treating atrophy m mammalian skin, b) preventing, retarding, and/or treating the appearance of dark, under-eye circles and puffy eyes, c) preventing, retarding, and/or treating sallowness of mammalian skm, d) preventing and/or retarding tanning of mammalian skm, e) desquamating, exfoliating, and/or increasing turnover of mammalian skin, f) regulating and/or reducing the size of pores in mammalian skin, g) regulating the oily and/or shmy appearance of mammalian skin, h) preventing, retarding, and/or treating post-inflammatory hyperpigmentation, and l) preventing and/or treating the appearance of cellulite m mammalian skm These methods are accomplished via
  • Mammalian keratinous tissue is subjected to a variety of msults by both extrinsic and intrinsic factors
  • extrinsic factors include ultraviolet radiation, environmental pollution, wmd, heat, infrared radiation, low humidity, harsh surfactants, abrasives, etc.
  • Intrinsic factors include chronological aging and other biochemical changes from within the skm Whether extrinsic or intrinsic, these factors result in visible signs of skin damage Typical skin damage includes thinning of the skin, which occurs naturally as one ages With such thinning, there is a reduction in the cells and blood vessels that supply the skin as well as a flattening of the dermal-epidermal junction that results in weaker mechanical resistance of this junction. See, for example, Oika ⁇ nen, "The Agmg of Skin Chronoagmg Versus Photoagmg," Photodermatol Photoimmunol Photomed , vol 7, pp.
  • phytosterols can stabilize cellular and extracellular components of keratinous tissue, particularly the outer cell membranes as well as membranes of various organelles
  • the phytosterol treated cells become stronger, more resistant, and are able to withstand higher levels of the above-described insults
  • compositions that contain specific phytosterols may be used to provide prophylactic as well as therapeutic treatments for keratinous tissue conditions
  • Applicants have found that such compositions may be useful for treating atrophy of the skin as well as sallowness, spider vessels, dark, under-eye circles, puffy eyes, promoting skin desquamation, exfoliation, and/or turnover, regulating and/or reducing pore size appearance, preventmg/retarding tanmng, regulating oily/shiny appearance, preventing/retarding post-mflammatory hyperpigmentation m mammalian skm, and preventing and/or treating the appearance of cellulite in mammalian skin
  • the present invention relates to methods for regulating the condition of mammalian keratmous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a composition comp ⁇ smg a) a safe and effective amount of one or more phytosterols selected from the group consistmg of ⁇ - sitosterol, campesterol, brassicasterol, ⁇ 5-avennasterol, lupenol, ⁇ -spmasterol, stigmasterol, their de ⁇ vatives, and combinations thereof, and b) a dermatologically acceptable carrier for the phytosterol
  • the above composition is suitable for thickening skin and preventing, retarding, and/or treating atrophy of mammalian skin, preventing, retarding, and/or treating the appearance of dark, under-eye circles and puffy eyes, preventmg, retarding, and/or treating sallowness of mammalian skm, preventing and/or retarding tanning of mammalian skin, desquamating, exfoliating, or mcreasing the turnover of mammalian skin, regulating and/or reducing the size of pores in mammalian skm, regulating oily/shmy appearance of mammalian skin, preventing, retardmg, and/or treatmg post-mflammatory hyperpigmentation, and preventmg and/or treating the appearance of cellulite in mammalian skin
  • compositions of the present invention can comprise, consist essentially of, or consist of, the essential components as well as optional ingredients described herein As used herein, "consisting essentially of means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods
  • keratmous tissue refers to keratm-containing layers disposed as the outermost protective covering of mammals which includes, but is not limited to, skin, hair, toenails, fingernails, cuticles, hooves, etc .
  • topical application means to apply or spread the compositions of the present invention onto the surface of the keratinous tissue.
  • compositions or components thereof so described are suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like.
  • safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit, preferably a positive keratinous tissue appearance or feel benefit, including independently or in combinations the benefits disclosed herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan.
  • post-inflammatory hyperpigmentation refers to the changes in melanin content as a response to an inflammatory event (e.g , acne, scratch, insect sting, sunburn, etc), especially in dark skm subjects.
  • an inflammatory event e.g , acne, scratch, insect sting, sunburn, etc
  • the terms “desquamation, exfoliation, and/or increasing turnover” as used herein mean the removal of the upper layers of the stratum corneum (comp ⁇ smg the horny and granular layers) Without intendmg to be limited by theory, it is believed that these benefits may be accomplished via chemical and physical means that remove these layers from the top down Additionally, it is possible to elicit exfoliation via a biological means that drives the turnover of the epidermal layers from the basal layers upwards. It is believed that this involves the process of keratinocyte proliferation as well as induction of differentiation. The latter leads to an elevation in keratinization levels as well, which ultimately lead to a reorganization of the upper epidermal layers that comp ⁇ se the stratum corneum and stratum granular layers.
  • oil and/or shiny appearance mean the glossy look mammalian skin tends to exhibit upon the excretion of oil, sebum, and/or sweat from the respective source gland.
  • compositions of the present invention are useful for topical application and for regulating keratinous tissue condition Regulation of keratinous tissue condition, especially human skm condition, is often required due to conditions that may be induced or caused by factors internal and/or external to the body.
  • "regulating skin condition” includes prophylactically regulating and/or therapeutically regulating skin condition, and may involve one or more of the following benefits: thickening of skm (i.e., building the epidermis and/or dermis layers of the skm and or the subcutaeous layers such as fat and muscle and where applicable the keratinous layers of the nail and hair shaft) to reduce skm atrophy, increasing the convolution of the dermal-epidermal border, non-melanin skin discoloration such as under eye circles, blotching (e g , uneven red coloration due to, e g , rosacea) (hereinafter referred to as "red blotchiness”), sallowness (pale color), discoloration
  • regulating skin condition is intended to include regulation of such signs irrespective of the mechanism of o ⁇ gm
  • compositions of the present invention including the essential and optional components thereof, are described in detail hereinafter Phytosterol
  • the topical compositions of the present invention comprise a safe and effective amount of one or more phytosterols selected from the group consisting of ⁇ -sitosterol, campesterol, brassicasterol, ⁇ 5- avennasterol, lupenol, ⁇ -spinasterol, stigmasterol, their derivatives, and combmations thereof More preferably, the phytosterol is selected from the group consisting of ⁇ -sitosterol, campesterol, brassicasterol, stigmasterol, their derivatives, and combinations thereof Even more preferably, the phytosterol is selected from the group consisting of ⁇ -sitosterol, campesterol, brassicasterol, stigmasterol, and combinations thereof Most preferably, the phytosterol is stigmasterol
  • Phytosterols can be synthetic or natural m origin and can be used as essentially pure compounds or mixtures of compounds (e g , extracts from natural sources) Phytosterols are generally found m the unsaponifiable portion of vegetable oils and fats and are available as free sterols, acetylated derivatives, sterol esters, ethoxylated or glycosidic derivatives More preferably, the phytosterols are free sterols As used herein, "phytosterol” mcludes isomers and tautomers of such and is commercially available from Aldrich Chemical Company (Milwaukee, Wisconsin), Sigma Chemical Company (St Louis, Missouri), and Fytokem Products, Inc (Saskatoon, SK, Canada)
  • the phytosterol preferably comprises from about 0 01% to about 99 99%, by weight of the composition, more preferably from about 0 01% to about 50%, even more preferably from about 0 1% to about 20%, still more preferably from about 0 2% to about 10%, and most preferably from about 0 5% to about 10% Dermatologically Acceptable Carrier
  • compositions of the present invention also comprise a dermatologically acceptable carrier for the phytosterol
  • a dermatologically acceptable carrier for the phytosterol
  • a safe and effective amount of carrier is from about 50% to about 99 99%, preferably from about 80% to about 99 9%, more preferably from about 90% to about 98%, and most preferably from about 90% to about 95% of the composition
  • the carrier can be in a wide variety of forms
  • emulsion carriers including, but not limited to, oil-in-water, water-in-oil, water-m-oil-in-water, and oil-in-water-in-sihcone emulsions, are useful herem
  • Preferred carriers comprise an emulsion such as oil-in-water emulsions and water-m-oil emulsions, e g , sihcone-m-water or water-in-si cone emulsions
  • emulsions such as oil-in-water emulsions and water-m-oil emulsions, e g , sihcone-m-water or water-in-si cone emulsions
  • a given component will distribute primarily into either the water or oil phase, depending on the water solubility/dispensability of the component in the composition
  • Phytosterol distributes primarily into the oil phase
  • Oil-in-water emulsions are especially preferred
  • Emulsions according to the present mvention generally contain a solution as described above and a lipid or oil Lipids and oils may be derived from animals, plants, or petroleum and may be natural or synthetic (I e , man-made) Preferred emulsions also contain a humectant, such as glycerin Emulsions will preferably further contain from about 1% to about 10%, more preferably from about 2% to about 5%, of an emulsifier, based on the weight of the carrier Emulsifiers may be nomonic, anionic or cationic Suitable emulsifiers are disclosed in, for example, U S Patent 3,755,560, issued August 28, 1973, Dickert et al , U S Patent 4,421,769, issued December 20, 1983, Dixon et al , and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986)
  • the emulsion may also contain an anti-foaming agent to minimize foaming upon application to the keratmous tissue
  • Anti-foammg agents include high molecular weight sihcones and other matenals well known m the art for such use
  • Suitable emulsions may have a wide range of viscosities, depending on the desired product form
  • Exemplary low viscosity emulsions which are preferred, have a viscosity of about 50 centistokes or less, more preferably about 10 centistokes or less, most preferably about 5 centistokes or less
  • Water-m-sihcone emulsions contain a continuous sihcone phase and a dispersed aqueous phase d) Continuous si cone phase
  • Preferred water- m-sihcone emulsions of the present invention comprise from about 1% to about 60%, preferably from about 5% to about 40%, more preferably from about 10% to about 20%, by weight of a continuous sihcone phase
  • the continuous sihcone phase exists as an external phase that contains or su ⁇ ounds the discontinuous aqueous phase described hereinafter
  • the continuous sihcone phase contains a polyorganosiloxane oil
  • a preferred water-m-sihcone emulsion system is formulated to provide an oxidatively stable vehicle for an optional retinoid
  • the continuous sihcone phase of these preferred emulsions comprises between about 50% and about 99 9% by weight of organopolysiloxane oil and less than about 50% by weight of a non-silicone oil
  • the continuous sihcone phase comprises at least about 50%, preferably from about 60% to about 99 9%, more preferably from about 70% to about 99 9%, and even more preferably from about 80% to about 99 9%, polyorganosiloxane oil by weight of the continuous sihcone phase, and up to about 50% non-silicone oils, preferably less about 40%, more preferably less than about 30%, even more preferably less than about 10%, and most preferably less than about 2%, by weight of the continuous sihcone phase
  • These prefe ⁇ ed emulsion systems provide
  • the organopolysiloxane oil for use m the composition may be volatile, non-volatile, or a mixture of volatile and non-volatile silicones
  • nonvolatile refers to those silicones that are liquid under ambient conditions and have a flash point (under one atmospheric of pressure) of or greater than about 100°C
  • volatile refers to all other sihcone oils
  • suitable organopolysiloxanes can be selected from a wide variety of silicones spanning a broad range of volatilities and viscosities
  • suitable organopolysiloxane oils include polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes
  • Polyalkylsiloxanes useful in the composition herein mclude polyalkylsiloxanes with viscosities of from about 0 5 to about 1,000,000 centistokes at 25°C
  • Such polyalkylsiloxanes can be represented by the general chemical formula R3S ⁇ O[R2S ⁇ O] x S ⁇ R3 wherein R is an alkyl group having from one to about 30 carbon atoms (preferably R is methyl or ethyl, more preferably methyl, also mixed alkyl groups can be used in the same molecule), and x is an integer from 0 to about 10,000, chosen to achieve the desired molecular weight which can range to over about 10,000,000
  • Commercially available polyalkylsiloxanes include the polydimefhylsiloxanes, which are also known as dimethicones, examples of which include the Vicasil® series sold by General Electric Company and the Dow Coming® 200 series sold by Dow Corning
  • suitable polydimefhylsiloxanes include Dow Corning® 200 fluid having a viscosity of 0 65 centistokes and a boiling point of 100°C, Dow Corning® 225 fluid havmg a viscosity of
  • Suitable dimethicones include those represented by the chemical formula
  • trimethylsiloxysihcate which is a polymeric material co ⁇ esponding to the general chemical formula [(CH2)3S ⁇ O ⁇ /2] x [S ⁇ 2]y, wherein x is an integer from about 1 to about 500 and y is an integer from about 1 to about 500
  • trimethylsiloxysihcate is sold as a mixture with dimethicone as Dow Coming® 593 fluid
  • Dimethiconols are also suitable for use m the composition These compounds can be represented by the chemical formulas R 3 S ⁇ O[R2S ⁇ O] ⁇ S ⁇ R 2 OH and HOR 2 S ⁇ O[R 2 S ⁇ O] x S ⁇ R2 ⁇ H wherein R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and x is an integer from 0 to about 500, chosen to achieve the desired molecular weight
  • R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and x is an integer from 0 to about 500, chosen to achieve the desired molecular weight
  • dimethiconols are typically sold as mixtures with dimethicone or cyclomethicone (e g Dow Commg® 1401, 1402, and 1403 fluids)
  • Polyalkylaryl siloxanes are also suitable for use in the composition
  • Polymethylphenyl siloxanes having viscosities from about 15 to about 65 centistokes at 25°C are especially useful
  • organopolysiloxanes selected from the group consisting of polyalkylsiloxanes, alkyl substituted dimethicones, cyclomethicones, t ⁇ methylsiloxysihcates, dimethiconols, polyalkylaryl siloxanes, and mixtures thereof More prefe ⁇ ed for use herein are polyalkylsiloxanes and cyclomethicones Prefe ⁇ ed among the polyalkylsiloxanes are dimethicones
  • the continuous sihcone phase may contain one or more non-silicone oils Concentrations of non-silicone oils in the continuous sihcone phase are preferably minimized or avoided altogether so as to further enhance oxidative stability of any retmoids in the compositions Suitable non- sihcone oils have a melting point of about 25°C or less under about one atmosphere of pressure
  • non-silicone oils suitable for use m the continuous sihcone phase are those well known m the chemical arts in topical personal care products in the form of water-m-oil emulsions, e g , mineral oil, vegetable oils, synthetic oils, semisynthetic oils, etc
  • compositions of the present invention comprise from about 30% to about 90%, more preferably from about 50% to about 85%, and most preferably from about 70% to about 80% of a dispersed aqueous phase
  • dispersed phase is a term well-known to one skilled m the art which means that the phase exists as small particles or droplets that are suspended in and surrounded by a continuous phase
  • the dispersed phase is also known as the internal or discontinuous phase
  • the dispersed aqueous phase is a dispersion of small aqueous particles or droplets suspended in and su ⁇ ounded by the continuous sihcone phase described hereinbefore
  • the aqueous phase can be water, or a combination of water and one or more water soluble or dispersible ingredients
  • water soluble or dispersible ingredients include thickeners, acids, bases, salts, chelants, gums, water-soluble or dispersible alcohols and polyols, buffers, preservatives, sunscreemng agents, colorings, and the like
  • compositions of the present invention will typically comprise from about 25% to about 90%, preferably from about 40% to about 80%, more preferably from about 60% to about 80%, water in the dispersed aqueous phase by weight of the composition
  • Emulsifier for dispersing the aqueous phase
  • the water-in-sihcone emulsions of the present invention preferably comprise an emulsifier
  • the composition contains from about 0 1% to about 10% emulsifier, more preferably from about 0 5% to about 7 5%, most preferably from about 1% to about 5%, emulsifier by weight of the composition
  • the emulsifier helps disperse and suspend the aqueous phase within the continuous sihcone phase
  • emulsifying agents can be employed herein to form the preferred water- ln-sihcone emulsion
  • Known or conventional emulsifying agents can be used in the composition, provided that the selected emulsifying agent is chemically and physically compatible with essential components of the composition, and provides the desired dispersion characteristics
  • Suitable emulsifiers include sihcone emulsifiers, non-sihcon-containing emulsifiers, and mixtures thereof, known by those skilled m the art for use in topical personal care products
  • these emulsifiers have an HLB value of or less than about 14, more preferably from about 2 to about 14, and most preferably from about 4 to about 14
  • Emulsifiers having an HLB value outside of these ranges can be used in combination with other emulsifiers to achieve an effective weighted average HLB for the combination that falls within these ranges
  • Sihcone emulsifiers are prefe ⁇ ed
  • sihcone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled in the art as sihcone surfactants
  • Useful sihcone emulsifiers include dimethicone copolyols These materials are polydimethylsiloxanes that have been modified to mclude polyether side chains such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains, and polyether chains containing moieties derived from both ethylene oxide and propylene oxide
  • Other examples include alkyl-modified dimethicone copolyols, I e , compounds that contain C2-C30 pendant side chains
  • Still other useful dimethicone copolyols include materials having various cationic, anionic, amphotenc, and zwitte ⁇ onic pendant moieties
  • dimethicone copolyol emulsifiers useful herein can be described by the following general structure
  • R is C1-C30 straight, branched, or cyclic alkyl and R ⁇ is selected from the group consistmg of
  • n is an mteger from 3 to about 10
  • R-> and R 4 are selected from the group consisting of H and Cl-
  • sihcone surfactants as depicted m the structures in the previous paragraph wherein R ⁇ is -(CH 2 ) n -0-R5, wherem R ⁇ is a cationic, anionic, amphotenc, or zwitteriomc moiety
  • Nonlimitmg examples of dimethicone copolyols and other sihcone surfactants useful as emulsifiers herein include polydimethylsiloxane polyether copolymers with pendant polyethylene oxide side chams, polydimethylsiloxane polyether copolymers with pendant polypropylene oxide side chams, polydimethylsiloxane polyether copolymers with pendant mixed polyethylene oxide and polypropylene oxide side chains, polydimethylsiloxane polyether copolymers with pendant mixed poly(ethylene)(propylene)ox ⁇ de side chains, polydimethylsiloxane polyether copolymers with pendant organobetaine side chains, polydimethylsiloxane polyether copolymers with pendant carboxylate side chains, polydimethylsiloxane polyether copolymers with pendant quaternary ammonium side chains, and also further modifications of the preceding copolymers containing pendant C2-C30 straight, branched, or
  • Dimethicone copolyol emulsifiers useful herein are described, for example, in U S Patent No 4,960,764, to Figueroa, Jr et al , issued October 2, 1990, European Patent No EP 330,369, to Sanoguerra, published August 30, 1989, G H Dah s, et al , "New Formulation Possibilities Offered by Sihcone Copolyols," Cosmetics & Toiletries, vol 110, pp 91-100, March 1995, M E Carlotti et al , "Optimization of W/O-S Emulsions And Study Of The Quantitative Relationships Between Ester Structure And Emulsion Properties," J Dispersion Science And Technology, 13(3), 315-336 (1992), P Hameyer, "Comparative Technological Investigations of Organic and Organosihcone Emulsifiers m Cosmetic Water-m-Oil Emulsion Preparations," HAPPI 28(4), pp 88-128 (1991), J Smid-
  • non-silicone-containmg emulsifiers useful herein are various non-ionic and anionic emulsifying agents such as sugar esters and polyesters, alkoxylated sugar esters and polyesters, C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated derivatives of C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated ethers of C1-C30 fatty alcohols, polyglyceryl esters of C1-C30 fatty acids, Cl- C30 esters of polyols, C1-C30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, and mixtures thereof
  • suitable emulsifiers are described, for example, m McCutcheon's, Detergents and Emulsifiers, North American Edition
  • Nonlimitmg examples of these non-sihcon-containing emulsifiers include polyethylene glycol 20 sorbitan monolaurate (Polysorbate 20), polyethylene glycol 5 soya sterol, Steareth-20, Ceteareth-20, PPG-2 methyl glucose ether distearate, Ceteth-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, Polysorbate 60, glyceryl stearate, PEG- 100 stearate, polyoxyethylene 20 sorbitan t ⁇ oleate (Polysorbate 85), sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, steareth-20, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, diethanolamine cetyl phosphate, glyceryl stearate, PEG
  • prefe ⁇ ed topical earners include oil-in-water emulsions, having a continuous aqueous phase and a hydrophobic, water-msoluble phase ("oil phase") dispersed therein
  • oil phase a hydrophobic, water-msoluble phase
  • suitable earners comprising oil-in-water emulsions are described in U.S. Pat. No. 5,073,371, to Turner, D J. et al., issued Dec. 17, 1991, and U.S. Pat. No. 5,073,372, to Turner, D.J. et al., issued Dec 17, 1991.
  • a prefe ⁇ ed oil-in-water emulsion comprises a stmcturmg agent to assist in the formation of a liquid crystalline gel network stmcture
  • the structuring agent assists m providing rheological characteristics to the composition that contribute to the stability of the composition.
  • the stmcturmg agent may also function as an emulsifier or surfactant.
  • Prefe ⁇ ed compositions of this invention comprise from about 0.5% to about 20%, more preferably from about 1% to about 10%, most preferably from about 1% to about 5%, by weight of the composition, of a structunng agent.
  • the prefe ⁇ ed structuring agents of the present invention are selected from the group consistmg of stea ⁇ c acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stea ⁇ c acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
  • More prefe ⁇ ed stmcturmg agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of stearyl alcohol having an average of about 21 ethylene oxide units (steareth-21), the polyethylene glycol ether of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof.
  • prefe ⁇ ed structuring agents are selected from the group consisting of stea ⁇ c acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth-2, steareth-21, and mixtures thereof.
  • Hydrophihc surfactant is selected from the group consisting of stea ⁇ c acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth-2, steareth-21, and mixtures thereof.
  • the prefe ⁇ ed oil-m-water emulsions comprise from about 0 05% to about 10%, preferably from about 1% to about 6%, and more preferably from about 1% to about 3% of at least one hydrophihc surfactant which can disperse the hydrophobic materials m the water phase (percentages by weight of the topical earner)
  • the surfactant at a minimum, must be hydrophihc enough to disperse in water.
  • Suitable surfactants include any of a wide variety of known cationic, anionic, zwitte ⁇ onic, and amphotenc surfactants See, McCutcheon's. Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation; U.S Patent 5,011,681, U.S. Patent 4,421,769; and U.S Patent 3,755,560, these references are incorporated herein by reference m their entirety.
  • the exact surfactant chosen will depend upon the pH of the composition and the other components present.
  • cationic surfactants especially dialkyl quaternary ammonium compounds, examples of which are described m U.S. Patent 5,151,209; U.S. Patent 5,151,210; U.S. Patent 5,120,532, U.S. Patent 4,387,090; U.S. Patent 3,155,591, U.S. Patent 3,929,678; U.S. Patent 3,959,461; McCutcheon's. Detergents & Emulsifiers. (North American edition 1979) M C Publishing Co., and Schwartz, et al., Surface Active Agents. Their Chemistry and Technology, New York: Interscience Publishers, 1949; which descriptions are incorporated herein by reference.
  • the cationic surfactants useful herein m clude catiomc ammonium salts such as those having the formula:
  • R 2 — N— R 3 R4 wherein R j , is an alkyl group having from about 12 to about 30 carbon atoms, or an aromatic, aryl or alkaryl group having from about 12 to about 30 carbon atoms; R2, R3, and R4 are independently selected from hydrogen, an alkyl group hav g from about 1 to about 22 carbon atoms, or aromatic, aryl or alkaryl groups havmg from about 12 to about 22 carbon atoms; and X is any compatible amon, preferably selected from the group consisting of chloride, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate, and mixtures thereof. Additionally, the alkyl groups of R j ,
  • R2, R3, and R4 can also contain ester and/or ether linkages, or hydroxy or amino group substituents (e.g., the alkyl groups can contain polyethylene glycol and polypropylene glycol moieties)
  • R j is an alkyl group having from about 12 to about 22 carbon atoms
  • R2 is selected from H or an alkyl group having from about 1 to about 22 carbon atoms
  • R3 and R4 are independently selected from H or an alkyl group having from about 1 to about 3 carbon atoms
  • X is as described previously.
  • R1 is an alkyl group havmg from about 12 to about 22 carbon atoms; R2, R3, and
  • R4 are selected from H or an alkyl group havmg from about 1 to about 3 carbon atoms; and X is as described previously.
  • cationic emulsifiers include ammo-amides, wherein m the above stmcture R1 is alternatively R5CONH-(CH2) n , wherein R5 is an alkyl group having from about 12 to about
  • n is an integer from about 2 to about 6, more preferably from about 2 to about 4, and most preferably from about 2 to about 3
  • Nonlimitmg examples of these cationic emulsifiers include stearamidopropyl PG-dimonmm chloride phosphate, behenamidopropyl PG dimonium chloride, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (mynstyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammomum tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof Especially prefe ⁇ ed is behenarmdopropyl PG dimonium chloride
  • Nonlimitmg examples of quaternary ammomum salt catiomc surfactants mclude those selected from the group consisting of cetyl ammomum chloride, cetyl ammonium bromide, lauryl ammomum chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl ammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammomum chloride, stearyl dimethyl ammonium bromide, cetyl t ⁇ methyl ammonium chloride, cetyl tnmethyl ammomum bromide, lauryl t ⁇ methyl ammomum bromide, lauryl tnmethyl ammomum bromide, stearyl tnmethyl ammonium chloride, stearyl tnmethyl
  • C30 alkyl carbon chain is derived from a tallow fatty acid or from a coconut fatty acid
  • tallow refers to an alkyl group derived from tallow fatty acids (usually hydrogenated tallow fatty acids), which generally have mixtures of alkyl chains m the C j g to C j g range
  • coconut refers to an alkyl group derived from a coconut fatty acid, which generally have mixtures of alkyl chams m the C j 2 to C14 range
  • Examples of quaternary ammomum salts derived from these tallow and coconut sources mclude ditallow dimethyl ammonium chloride, ditallow dimethyl ammonium methyl sulfate, d ⁇ (hydrogenated tallow) dimethyl ammonium chloride, d ⁇ (hydrogenated tallow) dimethyl ammonium acetate, ditallow dipropyl ammonium phosphate, ditallow dimethyl ammonium nitrate, d
  • More prefe ⁇ ed cationic surfactants are those selected from the group consisting of behenamidopropyl PG dimomum chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimy ⁇ styl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearamidopropyl PG-dimomum chloride phosphate, stearamidopropyl ethyldiammomum ethosulfate, stearamidopropyl dimethyl (mynstyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammomum lactate, and mixtures thereof.
  • Most prefe ⁇ ed cationic surfactants are those selected from the group consistmg of behenamidopropyl PG dimomum chlonde, dilauryl dimethyl ammomum chloride, distearyl dimethyl ammomum chloride, dimy ⁇ styl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, and mixtures thereof.
  • a prefe ⁇ ed combination of cationic surfactant and structuring agent is behenamidopropyl PG dimomum chloride and/or behenyl alcohol, wherein the ratio is preferably optimized to maintained to enhance physical and chemical stability, especially when such a combination contains ionic and/or highly polar solvents
  • This combination is especially useful for delivery of sunscreemng agents such as zinc oxide and octyl methoxycinnamate.
  • anionic surfactants are also useful herein. See, e g , U S Patent No. 3,929,678, to Laughhn et al , issued December 30, 1975, which is incorporated herein by reference in its entirety
  • anionic surfactants include the alkoyl lsethionates, and the alkyl and alkyl ether sulfates.
  • the alkoyl lsethionates typically have the formula RCO-OCH CH SO M wherein R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and tnethanolamine
  • R alkyl or alkenyl of from about 10 to about 30 carbon atoms
  • M is a water-soluble cation such as ammonium, sodium, potassium and tnethanolamine
  • Nonlimitmg examples of these lsethionates include those alkoyl lsethionates selected from the group consisting of ammonium cocoyl lsethionate, sodium cocoyl lsethionate, sodium lauroyl lsethionate, sodium stearoyl lsethionate, and mixtures thereof.
  • alkyl and alkyl ether sulfates typically have the respective formulae ROSO M and
  • RO(C H O) SO M wherem R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, x is from about 1 to about 10, and M is a water-soluble cation such as ammonium, sodium, potassium and tnethanolamine
  • R is alkyl or alkenyl of from about 10 to about 30 carbon atoms
  • x is from about 1 to about 10
  • M is a water-soluble cation such as ammonium, sodium, potassium and tnethanolamine
  • anionic surfactants is the water-soluble salts of the orgamc, sulfu ⁇ c acid reaction products of the general formula- R— SO -M wherein R is chosen from the group consisting of a straight or branched chain, saturated aliphatic hydrocarbon radical having from about 8 to about 24, preferably about 10 to about 16, carbon atoms, and M is a cation
  • Still other anionic synthetic surfactants include the class designated as succmamates, olefin sulfon
  • soaps (1 e alkali metal salts, e g , sodium or potassium salts) of fatty acids, typically havmg from about 8 to about 24 carbon atoms, preferably from about 10 to about 20 carbon atoms
  • the fatty acids used in making the soaps can be obtained from natural sources such as, for instance, plant or animal-derived glyce ⁇ des (e g , palm oil, coconut oil, soybean oil, castor oil, tallow, lard, etc )
  • the fatty acids can also be synthetically prepared Soaps are described in more detail in U S Patent No 4,557,853
  • amphotenc and zwittenomc surfactants are also useful herem
  • amphotenc and zwitte ⁇ omc surfactants which can be used in the compositions of the present invention are those which are broadly descnbed as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably Cg - C j g) and one contains an anionic water solubihzing group, e g , carboxy, sulfonate, sulfate, phosphate, or phosphonate
  • Examples are alkyl lmino acetates, and lminodialkanoates and aminoalkanoates of the formulas RNrCH remember) CO cursML and RNH(CH refrain) COappelM
  • m is from 1 to 4
  • R is a Cg-C22 alkyl or alkenyl
  • M is H, alkali metal, alkaline earth metal ammomum, or alkanolammomum
  • lmidazolinium and ammonium derivatives Specific examples of suitable amphotenc surfactants include sodium 3-dodecyl-am ⁇ noprop ⁇ onate, sodium 3-dodecylammopropane sulfonate, N-alkyltaurmes such as the one prepared by reacting dodecylamme with sodium lsethionate according to the teaching of U S Patent 2,658,072 which is incorporated herein by reference in its entirety, N-higher alkyl aspartic acids such as those produced according to the teaching of U S Patent 2,438,091 which is incorporated herein by reference in its entirety, and the products sold under the trade name "Miranol" and described m U S Patent 2,
  • amphotenc or zwittenomc surfactants are the betames
  • betaines include the higher alkyl betaines, such as coco dimethyl carboxymethyl betame, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betame, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betaine (available as Lonzaine 16SP from Lonza Corp ), lauryl b ⁇ s-(2-hydroxyethyl) carboxymethyl betaine, stearyl b ⁇ s-(2-hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl b ⁇ s-(2-hydroxypropyl)alpha-carboxyethyl betaine, coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl dimethyl s
  • amphotenc and zwittenomc surfactants include the sultames and hydroxysultaines such as cocamidopropyl hydroxysultaine (available as Mirataine CBS from Rhone-Poulenc), and the alkanoyl sarcosinates co ⁇ esponding to the formula RCON(CH )CH CH CO M wherein R is alkyl or alkenyl of about 10 to about 20 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and trialkanolamme (e g , tnethanolamine), a prefe ⁇ ed example of which is sodium lauroyl sarcosinate (in) Water
  • the prefe ⁇ ed oil-m-water emulsion comprises from about 25% to about 98%, preferably from about 65%o to about 95%, more preferably from about 70% to about 90% water by weight of the topical earner
  • the hydrophobic phase is dispersed m the contmuous aqueous phase
  • the hydrophobic phase may contain water insoluble or partially soluble materials such as are known in the art, including but not limited to the silicones described herein m reference to sihcone-m-water emulsions, and other oils and hpids such as described above m reference to emulsions
  • compositions of the subject invention may comprise a dermatologically acceptable emollient
  • emollient refers to a material useful for the prevention or relief of dryness, as well as for the protection of the skm
  • emollients are known and may be used herem Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol 1, pp 32-43 (1972), incorporated herein by reference, contains numerous examples of materials suitable as an emollient
  • a prefe ⁇ ed emollient is glycerin
  • Glycerin is preferably used m an amount of from or about 0 001 to or about 20%, more preferably from or about 0 01 to or about 10%, most preferably from or about 0 1 to or about 5%, e g , 3%
  • Lotions and creams according to the present invention generally comprise a solution earner system and one or more emollients Lotions typically comprise from about 1% to about 20%, preferably from about 5% to about 10%, of emollient, from about 50%> to about 90%, preferably from about 60% to about 80%, water, and phytosterol in the above described amounts
  • a cream typically compnses from about 5% to about 50%, preferably from about 10% to about 20%, of emollient, from about 45% to about 85%, preferably from about 50% to about 75%, water, and the phytosterol m the above descnbed amounts
  • Ointments of the present invention may comprise a simple earner base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous), absorption ointment bases which absorb water to form emulsions, or water soluble earners, e g , a water soluble solution carrier Ointments may further comprise a thickening agent, such as described m Sagarin, Cosmetics, Science and Technology. 2nd Edition, Vol 1, pp 72-73 (1972), incorporated herein by reference, and/or an emollient
  • an ointment may comprise from about 2% to about 10% of an emollient, from about 0 1% to about 2% of a thickening agent, and phytosterol in the above descnbed amount
  • compositions of this invention useful for cleansing are formulated with a suitable earner, e g , as described above, and preferably contam, in addition to the phytosterol m the above described amounts, from about 1% to about 90%, more preferably from about 5% to about 10%, of a dermatologically acceptable surfactant
  • the surfactant is suitably selected from anionic, nonionic, zwittenomc, amphotenc and ampholytic surfactants, as well as mixtures of these surfactants
  • Such surfactants are well known to those skilled in the detergency art
  • Nonlimitmg examples of possible surfactants include ⁇ soceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, and sodium lauryl sulfate See U S Patent No 4,800,197, to Kowcz et al , issued January 24, 1989, which is incorporated herein by reference m its entirety, for exemplary surfactants useful herein Examples of a broad variety of additional surfact
  • the physical form of the cleansing compositions is not critical
  • the compositions can be, for example, formulated as toilet bars, liquids, shampoos, bath gels, hair conditioners, hair tonics, pastes, or mousses
  • Toilet bars are most prefe ⁇ ed smce this is the form of cleansing agent most commonly used to wash the skm
  • Rinse-off cleansmg compositions, such as shampoos require a delivery system adequate to deposit sufficient levels of actives on the skin and scalp
  • a prefe ⁇ ed delivery system mvolves the use of insoluble complexes
  • U S Patent 4,835,148, Barford et al issued May 30, 1989
  • compositions of the present invention may also be in the form of cosmetics Suitable cosmetic forms include, but are not limited to, foundations, lipsticks, rouges, mascaras, and the like
  • Such cosmetic products may include conventional ingredients such as oils, colorants, pigments, emollients, fragrances, waxes, stabilizers, and the like
  • Exemplary earners and such other ingredients which are suitable for use herem are descnbed, for example, m copending patent application Serial No 08/430,961, filed on April 28, 1995 m the names of Marcia L Canter, Brain D Barford, and Brian D Hofrichter, and U K Patent Application GB 2274585-A, published on Jan 23, 1993 Optional Components
  • compositions of the present invention may contain a variety of other ingredients such as are conventionally used in a given product type provided that they do not unacceptably alter the benefits of the invention
  • the optional components should be suitable for application to keratinous tissue, that is, when incorporated into the composition they are suitable for use m contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound medical judgment
  • CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes a wide variety of nonlimitmg cosmetic and pharmaceutical ingredients commonly used m the skin care industry, which are suitable for use in the compositions of the present invention
  • these ingredient classes include abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents, etc (e g , clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents, anti-cakmg agents, antifoaming agents,
  • the actives useful herein can be categorized by the benefit they provide or by their postulated mode of action
  • the actives useful herein can in some instances provide more than one benefit or operate via more than one mode of action Therefore, classifications herein are made for the sake of convemence and are not intended to limit the active to that particular application or applications listed
  • a safe and effective amount of a desquamation active may be added to the compositions of the present invention, more preferably from about 0 1% to about 10%, even more preferably from about 0.2% to about 5%, also preferably from about 0 5% to about 4%, by weight of the composition
  • Desquamation actives enhance the skin appearance benefits of the present invention For example, the desquamation actives tend to improve the texture of the skm (e g , smoothness)
  • One desquamation system that is suitable for use herein comprises sulfhydryl compounds and zwittenomc surfactants and is described m copendmg application Serial No 08/480,632, filed on June 7, 1995 m the name of Donald L Bissett, conesponding to PCT Application No U S 95/08136, filed 6/29/95
  • Another desquamation system that is suitable for use herem comprises salicylic acid and zwittenomc surfactants and is described in copending patent application Serial No 08/554,944,
  • compositions of the present invention may comprise a safe and effective amount of one or more anti-acne actives
  • useful anti-acne actives include resorcmol, sulfur, salicylic acid, erythromycin, zinc, etc
  • suitable anti-acne actives are described m further detail in U S Patent No 5,607,980, issued to McAtee et al, on March 4, 1997
  • compositions of the present invention may further comprise a safe and effective amount of one or more anti-wrinkle actives or anti-atrophy actives
  • anti-wrmkle/anti-atrophy actives suitable for use in the compositions of the present invention include sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives, a prefe ⁇ ed example of which is N-acetyl- L-cysteine, thiols, e g ethane thiol, hydroxy acids, phytic acid, hpoic acid, lysophosphatidic acid, skin peel agents (e.g., phenol and the like), flavonoids (e g , flavanones, chalcones, isoflavones, flavones, etc.), terpene alcohols (e.g., famesol), vitamin B 3 compounds and retmoids which enhance the keratmous
  • compositions of the present invention may comprise a safe and effective amount of a vitamm B3 compound.
  • Vitamm B 3 compounds are particularly useful for regulating skin condition as described m co-pendmg U S Application Serial No. 08/834,010, filed April 1 1, 1997 (co ⁇ esponding to international publication WO 97/39733 Al, published October 30, 1997).
  • the compositions preferably comprise from about 0 01% to about 50%, more preferably from about 0.1% to about 10%, even more preferably from about 0 5% to about 10%, and still more preferably from about 1% to about 5%, most preferably from about 2% to about 5%, by weight of the composition, of the vitamin B3 compound.
  • vitamin B3 compound means a compound havmg the formula:
  • R is - CONH2 (i.e., macinamide), - COOH (i.e., mcotinic acid) or - CH2OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregomg.
  • CONH2 i.e., macinamide
  • COOH i.e., mcotinic acid
  • CH2OH i.e., nicotinyl alcohol
  • Exemplary derivatives of the foregomg vitamin B3 compounds include mcotmic acid esters, including non-vasodilatmg esters of nicotinic acid (e g , tocopheryl nicotinate), mcotmyl ammo acids, nicotinyl alcohol esters of carboxy c acids, nicotinic acid N-oxide and macinamide N-oxide
  • Suitable vitamm B3 compounds are well known m the art and are commercially available from a number of sources, e.g , the Sigma Chemical Company (St. Louis, MO); ICN Biomedicals, Inc. (Irvin, CA) and Aldrich Chemical Company (Milwaukee, WI).
  • the vitamin compounds may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • compositions of the present invention may also comprise a retmoid
  • retinoid includes all natural and/or synthetic analogs of Vitamm A or retinol-hke compounds which possess the biological activity of Vitamm A m the skin as well as the geometric isomers and stereoisomers of these compounds
  • the retmoid is preferably retmol, retinol esters (e g , C - C22 alkyl esters of retmol, including retinyl palmitate, retinyl acetate, retmyl propionate), retinal, and/or retinoic acid (including all- trans retmoic acid and/or 13-c ⁇ s-retmo ⁇ c acid), more preferably retmoids other than retinoic acid
  • retinoic acid including all- trans retmoic acid and/or 13-c ⁇ s-retmo ⁇ c acid
  • these compounds are well known in the art and are commercially available from a number
  • the retinoid may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e g , plant) sources
  • the retinoid is preferably substantially pure, more preferably essentially pure
  • compositions of this invention may contain a safe and effective amount of the retmoid, such that the resultant composition is safe and effective for regulating keratinous tissue condition, preferably for regulating visible and/or tactile discontinuities in skm, more preferably for regulating signs of skin agmg, even more preferably for regulating visible and/or tactile discontinuities in skm texture associated with skin agmg
  • the compositions preferably contain from or about 0 005% to or about 2%, more preferably 0 01% to or about 2%, retinoid Retinol is most preferably used in an amount of from or about 0 01% to or about 0 15%, retinol esters are most preferably used m an amount of from or about 0 01% to or about 2% (e g , about 1%), retmoic acids are most preferably used in an amount of from or about 0 01% to or about 0 25%, tocopheryl-retmoate, adapalene, and
  • compositions of the present invention contain both a retmoid and a Vitamin B3 compound
  • the retinoid is preferably used in the above amounts
  • the vitamin B3 compound is preferably used in an amount of from or about 0 1% to or about 10%, more preferably from or about 2% to or about 5%
  • compositions of the present invention may include a safe and effective amount of an anti- oxidant radical scavenger
  • the anti-oxidant/radical scavenger is especially useful for providing protection against UV radiation that can cause increased scaling or texture changes m the stratum corneum and against other environmental agents, which can cause skin damage
  • a safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0 1% to about 10%, more preferably from about 1% to about 5%, of the composition
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid denvatives (e g , magnesium ascorbyl phosphate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5J,8-tetramethylchroman-2-carboxyhc acid (commercially available under the tradename Trolox ⁇ ), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, hpoic acid, amines (e g , N,N-d ⁇ ethylhydroxylarmne, amino- guamdine), sulfhydryl compounds (e g , glutathione), dihydroxy fuma ⁇ c
  • compositions of the present invention may also comp ⁇ se a safe and effective amount of a chelator or chelatmg agent
  • chelator or “chelatmg agent” means an active agent capable of removing a metal ion from a system by forming a complex so that the metal ion cannot readily participate in or catalyze chemical reactions
  • the inclusion of a chelatmg agent is especially useful for providing protection against UV radiation that can contribute to excessive scaling or skin texture changes and against other environmental agents, which can cause skin damage
  • a safe and effective amount of a chelatmg agent may be added to the compositions of the subject invention, preferably from about 0 1% to about 10%, more preferably from about 1% to about 5%, of the composition
  • Exemplary chelators that are useful herein are disclosed m U S Patent No 5,487,884, issued 1/30/96 to Bissett et al , International Publication No 91/16035, Bush et al , published 10/31/95, and International Publication No 91/16034, Bush et al , published 10/31/95
  • Prefe ⁇ ed chelators useful in compositions of the subject invention are fu ⁇ ldioxime and derivatives thereof Flavonoids
  • compositions of the present invention may optionally comprise a flavonoid compound
  • Flavonoids are broadly disclosed in U S Patents 5,686,082 and 5,686,367, both of which are herein incorporated by reference
  • Flavonoids suitable for use in the present invention are flavanones selected from the group consisting of unsubstiruted flavanones, mono-substituted flavanones, and mixtures thereof, chalcones selected from the group consisting of unsubstituted chalcones, mono-substituted chalcones, di- substituted chalcones, tri-substituted chalcones, and mixtures thereof; flavones selected from the group consisting of unsubstituted flavones, mono-substituted flavones, di-substiruted flavones, and mixtures thereof; one or more lsoflavones, couma ⁇ ns selected from the group consisting of unsubstituted coumarin
  • substituted means flavonoids wherein one or more hydrogen atom of the flavonoid has been independently replaced with hydroxyl, C1-C8 alkyl, C1-C4 alkoxyl, O-glycoside, and the like or a mixture of these substituents.
  • suitable flavonoids include, but are not limited to, unsubstituted flavanone, mono- hydroxy flavanones (e.g , 2'-hydroxy flavanone, 6-hydroxy flavanone, 7-hydroxy flavanone, etc.), mono- alkoxy flavanones (e.g., 5-methoxy flavanone, 6-methoxy flavanone, 7-methoxy flavanone, 4'-methoxy flavanone, etc.), unsubstituted chalcone (especially unsubstituted trans-chalcone), mono-hydroxy chalcones (e g., 2'-hydroxy chalcone, 4'-hydroxy chalcone, etc ), di-hydroxy chalcones (e.g., 2', 4-d ⁇ hydroxy chalcone, 2',4'-d ⁇ hydroxy chalcone, 2,2'-d ⁇ hydroxy chalcone, 2',3-d ⁇ hydroxy chalcone, 2',5'-d ⁇ hydroxy chalcone, etc.
  • Prefe ⁇ ed for use herein are unsubstituted flavanone, methoxy flavanones, unsubstituted chalcone, 2', 4-d ⁇ hydroxy chalcone, and mixtures thereof Most prefe ⁇ ed are unsubstituted flavanone, unsubstituted chalcone (especially the trans isomer), and mixtures thereof.
  • Flavonoid compounds useful herein are commercially available from a number of sources, e.g., Indof ⁇ ne Chemical Company, Inc. (Somerville, New Jersey), Steraloids, Inc (Wilton, New Hampshire), and Aldrich Chemical Company, Inc. (Milwaukee, Wisconsm).
  • the herein described flavonoid compounds are preferably present in the instant invention at concentrations of from about 0 01% to about 20%, more preferably from about 0.1% to about 10%, and most preferably from about 0.5% to about 5%
  • a safe and effective amount of an anti-inflammatory agent may be added to the compositions of the present invention, preferably from about 0.1% to about 10%, more preferably from about 0.5% to about 5%, of the composition
  • the anti-inflammatory agent enhances the skm appearance benefits of the present mvention, e g , such agents contribute to a more uniform and acceptable skin tone or color
  • the exact amount of anti-inflammatory agent to be used m the compositions will depend on the particular anti- mflammatory agent utilized smce such agents vary widely m potency
  • Steroidal anti-inflammatory agents including but not limited to, corticosteroids such as hydrocortisone, hydroxylt ⁇ amcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desomde, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlo ⁇ sone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetomde, fludrocortisone, flumethasone pivalate, fluosmolone acetomde, fluocmonide, flucortme butylesters, fluocortolone, flupredmdene (fluprednyhdene) acetate, flurandrenolone, halcrnonide, hydrocortisone acetate, hydrocortisone butyrate
  • a second class of anti-inflammatory agents which is useful m the compositions, mcludes the nonsteroidal anti-inflammatory agents
  • the varieties of compounds encompassed by this group are well known to those skilled m the art
  • composition invention examples include, but are not limited to
  • the oxicams such as piroxicam, lsoxicam, tenoxicam, sudoxicam, and CP-14, 304,
  • sahcylates such as aspirin, disalcid, benorylate, trihsate, safapryn, solp ⁇ n, diflunisal, and fendosal
  • acetic acid derivatives such as diclofenac, fenclofenac, mdomethacm, suhndac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacm, fentiazac, zomepirac, clmdanac, oxepinac, felbinac, and ketorolac,
  • the fenamates such as mefenamic, meclofenamic, flufenamic, mflumic, and tolfenamic acids
  • the propiomc acid derivatives such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, mdopropfen, pirprofen, carprofen, oxaprozm, pranoprofen, miroprofen, tioxaprofen, suprofen, a mnoprofen, and tiaprofemc, and
  • the pyrazoles such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and t ⁇ methazone
  • non-steroidal anti-mflammatory agents may also be employed, as well as the dermatologically acceptable salts and esters of these agents
  • etofenamate a flufenamic acid derivative
  • ibuprofen, naproxen, ketoprofen, flufenamic acid, etofenamate, aspirm, mefenamic acid, meclofenamic acid, piroxicam and felbmac are prefe ⁇ ed
  • ibuprofen, naproxen, ketoprofen, etofenamate aspirm and flufenamic acid are most prefe ⁇ ed
  • agents are useful in methods of the present invention
  • Such agents may suitably be obtained as an extract by suitable physical and/or chemical isolation from natural sources (e g , plants, fungi, by-products of microorganisms)
  • natural sources e g , plants, fungi, by-products of microorganisms
  • Guggal extracted from plants in the genus Commiphora, particularly Commiphora Mukul
  • kola extract chamomile
  • red clover extract and sea whip extract
  • Additional anti-inflammatory agents useful herem include allantom and compounds of the Licorice (the plant genus/species Glvcy ⁇ hiza glabra) family, including glycyrrhetic acid, glycy ⁇ hizic acid, and derivatives thereof (e g , salts and esters)
  • Suitable salts of the foregoing compounds mclude metal and ammomum salts
  • Suitable esters include C2 - C24 saturated or unsaturated esters of the acids, preferably
  • CI Q - C24 more preferably C j g - C24
  • Specific examples of the foregoing include oil soluble liconce extract, the glycy ⁇ hizic and glycy ⁇ hetic acids themselves, monoammonium glycy ⁇ hizinate, monopotassium glycy ⁇ hizinate, dipotassium glycy ⁇ hizinate, 1-beta-glycy ⁇ het ⁇ c acid, stearyl glycy ⁇ hetinate, and 3-stearyloxy-glycy ⁇ het ⁇ mc acid, and disodium 3-succ ⁇ nyloxy-beta-glycy ⁇ het ⁇ nate Stearyl glycy ⁇ hetinate is prefe ⁇ ed
  • the active component of these anti-inflammatory agents may also be obtained via extraction from natural sources or prepared synthetically Anti-Celluhte Agents
  • compositions of the present invention may also comprise a safe and effective amount of an anti-celluhte agent Suitable agents may mclude, but are not limited to, xanthine compounds (e g , caffeine, theophylline, theobromine, and ammophylline)
  • xanthine compounds e g , caffeine, theophylline, theobromine, and ammophylline
  • compositions of the present invention may also comprise a safe and effective amount of a topical anesthetic
  • topical anesthetic drags mclude benzocame, hdocaine, bupivacaine, chlorprocame, dibucaine, etidocame, mepivacame, tetracaine, dyclomne, hexylcaine, procame, cocaine, ketamine, pramoxme, phenol, and pharmaceutically acceptable salts thereof
  • compositions of the present invention may comprise a tanning active When present, it is preferable that the compositions comprise from about 0 1% to about 20%, more preferably from about 2% to about 7%, and most preferably from about 3% to about 6%, by weight of the composition, of dihydroxyacetone as an artificial tanning active
  • Dihydroxyacetone which is also known as DHA or l,3-d ⁇ hydroxy-2-propanone, is a white to off- white, crystalline powder
  • This material can be represented by the chemical formula C3H6O3 and the following chemical stmcture
  • the compound can exist as a mixture of monomers and dimers, with the dimers predommatmg m the solid crystalline state Upon heating or meltmg, the dimers break down to yield the monomers This conversion of the dimenc form to the monome ⁇ c form also occurs in aqueous solution Dihydroxyacetone is also known to be more stable at acidic pH values See The Merck Index, Tenth Edition, entry 3167, p 463 (1983), and "Dihydroxyacetone for Cosmetics", E Merck Technical Bulletin, 03-304 110, 319 897, 180 588
  • compositions of the present invention may comprise a skin lightening agent
  • the compositions preferably comp ⁇ se from about 0 1% to about 10%, more preferably from about 0 2% to about 5%, also preferably from about 0 5% to about 2%, by weight of the composition, of a skm lightening agent
  • Suitable skin lightening agents mclude those known in the art, including kojic acid, arbutin, ascorbic acid and de ⁇ vatives thereof, e g , magnesium ascorbyl phosphate or sodium ascorbyl phosphate or other salts of ascorbyl phosphate
  • Skin lightening agents suitable for use herem also include those described in copending patent application Serial No 08/479,935, filed on June 7, 1995 in the name of Hillebrand, co ⁇ esponding to PCT Application No U S 95/07432, filed 6/12/95, and copending patent application Serial No 08/390,152, filed on February 24, 1995 in the names of Kalla L Kvalnes, Mitchell A De
  • compositions of the present invention may comprise an antimicrobial or antifungal active
  • Such actives are capable of destroying microbes, preventing the development of microbes or preventmg the pathogenic action of microbes
  • a safe and effective amount of an antimicrobial or antifungal active may be added to the present compositions, preferably, from about 0 001% to about 10%, more preferably from about 0 01% to about 5%, and most preferably from about 0 05% to about 2%
  • antimicrobial and antifungal actives examples include ⁇ -lactam drugs, qumolone drags, ciprofloxacm, norfloxacin, tetracycline, erythromycm, amikacin, 2,4,4'-tnchloro-2'-hydroxy diphenyl ether, 3,4,4'-t ⁇ chloroban ⁇ l ⁇ de, phenoxyethanol, phenoxy propanol, phenoxyisopropanol, doxycyclme, capreomycin, chlorhexidine, chlortetracyclme, oxytetracyclme, clmdamycm, ethambutol, hexamidme lsethionate, metronidazole, pentamidine, gentamicin, kanamycin, hneomycin, methacychne, methenamine, minocychne, neomycin, netilmicm, paromomycm, streptomycin, tobramycin, miconazo
  • actives useful herein include those selected from the group consisting of salicylic acid, benzoyl peroxide, 3-hydroxy benzoic acid, glycohc acid, lactic acid, 4-hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutano ⁇ c acid, 2-hydroxypentano ⁇ c acid, 2-hydroxyhexano ⁇ c acid, cis- retmoic acid, trans-retmoic acid, retinol, phytic acid, N-acetyl-L-cysteme, hpoic acid, azelaic acid, arachidonic acid, benzoylperoxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetaminophen, resorcmol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-t ⁇ chloro-2'-hydroxy diphenyl ether, 3,
  • compositions of the subject invention may optionally contain a sunscreen active
  • sunscreen active includes both sunscreen agents and physical sunblocks
  • Suitable sunscreen actives may be organic or inorganic
  • a wide variety of conventional sunscreen actives are suitable for use herein Sagarm, et al , at Chapter VIII, pages 189 et seq , of Cosmetics Science and Technology (1972), discloses numerous suitable actives
  • Specific suitable sunscreen actives mclude, for example p-ammobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters, p-dimethylaminobenzoic acid), anthramlates (I e , o-amino- benzoates, methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpmyl, and cyclohexenyl esters),
  • 2-ethylhexyl-p-methoxyc ⁇ nnamate commercially available as PARSOL MCX
  • 4,4'-t- butyl methoxydibenzoyl-methane commercially available as PARSOL 1789
  • 2-hydroxy-4- methoxybenzophenone octyldimethyl-p-ammobenzoic acid, digalloylt ⁇ oleate, 2,2-d ⁇ hydroxy-4- methoxybenzophenone, ethyl-4-(bis(hydroxy-propyl))armnobenzoate
  • 2-ethylhexyl-2-cyano-3,3- diphenylacrylate 2-ethylhexyl-sahcylate
  • glyceryl-p-aminobenzoate 3,3,5-tn-methylcyclohexylsahcylate, methylanthramlate, p-dimethyl-ammobenzoic acid or aminobenzoate
  • More prefe ⁇ ed organic sunscreen actives useful in the compositions useful in the subject invention are 2-ethylhexyl-p-methoxycmnamate, butylmethoxydibenzoyl-methane, 2-hydroxy-4- methoxybenzo-phenone, 2-phenylbenz ⁇ m ⁇ dazole-5-sulfon ⁇ c acid, octyldimethyl-p-aminobenzoic acid, octocrylene, zmc oxide, titanium dioxide, and mixtures thereof
  • sunscreen actives such as those disclosed in U S Patent No 4,937,370 issued to Sabatelh on June 26, 1990, and U S Patent No 4,999,186 issued to Sabatelh & Spirnak on March 12, 1991
  • the sunscreenmg agents disclosed therein have, m a single molecule, two distinct chromophore moieties, which exhibit different ultra-violet radiation absorption spectra
  • One of the chromophore moieties absorbs predominantly m the UVB radiation range and the other absorbs strongly m the UVA radiation range
  • Prefe ⁇ ed members of this class of sunscreemng agents are 4-N, N-(2-ethylhexyl) methyl- ammobenzoic acid ester of 2,4-d ⁇ hydroxybenzophenone, N, N-d ⁇ -(2-ethylhexyl)-4-am ⁇ nobenzo ⁇ c acid ester with 4-hydroxyd ⁇ benzoylmethane, 4-N, N-(2-ethylhexyl) methyl-ammobenzoic acid ester with 4- hydroxydibenzoylmethane, 4-N, N-(2-ethylhexyl) methyl-ammobenzoic acid ester of 2-hydroxy-4-(2- hydroxyethoxy) benzophenone, 4-N, N-(2-ethylhexyl)-methylam ⁇ nobenzo ⁇ c acid ester of 4-(2- hydroxyethoxy) dibenzoylmethane, N,N-d ⁇ -(2-ethylhex
  • sunscreen actives include 4,4'-t-butylmethoxyd ⁇ benzoylmethane, 2- ethylhexyl-p-methoxycinnamate, phenyl benzimidazole sulfomc acid, octocrylene, zmc oxide, and titamum dioxide, and mixtures thereof
  • a safe and effective amount of the sunscreen active is used, typically from about 1 % to about 20%, more typically from about 2% to about 10% by weight of the composition Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF)
  • compositions of the present invention may comprise a conditioning agent selected from the group consistmg of humectants, moisturizers, or skm conditioners
  • a conditioning agent selected from the group consistmg of humectants, moisturizers, or skm conditioners
  • these materials include, but are not limited to, guamdine, urea, glycolic acid and glycolate salts (e g ammonium and quaternary alkyl ammomum), salicylic acid, lactic acid and lactate salts (e g , ammonium and quaternary alkyl ammonium), aloe vera in any of its variety of forms (e g , aloe vera gel), polyhydroxy compounds such as sorbitol, mannitol, glycerol, hexanet ⁇ ol, butanet ⁇ ol, propylene glycol, butylene
  • esters are derived from a sugar or polyol moiety and one or more carboxyhc acid moieties
  • ester materials are further described in, U S Patent No 2,831,854, U S Patent No 4,005,196, to Jandacek, issued January 25, 1977, U S Patent No 4,005,195, to Jandacek, issued January 25, 1977, U S Patent No 5,306,516, to Letton et al, issued April 26, 1994, U S Patent No 5,306,515, to Letton et al, issued April 26, 1994, U S Patent No 5,305,514, to Letton et al, issued April 26, 1994, U S Patent No 4,797,300, to Jandacek et al, issued January 10, 1989, U S Patent No 3,963,699, to Rizzi et al, issued June 15, 1976, U S Patent No 4,518,772, to Volpenhein, issued May 21, 1985, and U S Patent No 4,517,360
  • the conditioning agent is selected from the group consistmg of glycerol, urea, guamdme, sucrose polyester, and combinations thereof
  • Thickening Agent (including thickeners and gelling agents)
  • compositions of the present invention can comprise one or more thickening agents, preferably from about 0 1% to about 5%, more preferably from about 0 1%> to about 3%, and most preferably from about 0 25% to about 2%, by weight of the composition
  • Nonlimitmg classes of thickening agents include those selected from the group consisting of a) Carboxyhc Acid Polymers
  • polymers are crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosshnkmg agent contains two or more carbon-carbon double bonds and is derived from a polyhyd ⁇ c alcohol
  • polymers useful in the present invention are more fully described in U S Patent No 5,087,445, to Haffey et al, issued February 11, 1992, U S Patent No 4,509,949, to Huang et al, issued April 5, 1985, U S Patent No 2,798,053, to Brown, issued July 2, 1957, and in CTFA International Cosmetic Ingredient Dictionary, Fourth Edition, 1991, pp 12 and 80
  • carboxyhc acid polymers examples include the carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytntol
  • the carbomers are available as the Carbopol® 900 series from B F Goodrich (e g ,
  • carboxyhc acid polymeric agents include copolymers of CJQ.
  • alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain
  • crosslinkmg agent is an allyl ether of sucrose or pentaerytntol
  • copolymers are known as acrylates/C ⁇ 0 3 o alkyl acrylate crosspolymers and are commercially available as Carbopol® 1342, Carbopol® 1382, Pemulen TR-1, and Pemulen TR-2, from B F Goodrich
  • carboxyhc acid polymer thickeners useful herein are those selected from the group consistmg of carbomers, acrylates/C 10 -C 30 alkyl acrylate crosspolymers, and mixtures thereof b) Crosslinked Polyacrylate Polymers
  • compositions of the present invention can optionally comprise crosslinked polyacrylate polymers useful as thickeners or gelling agents including both cationic and noniomc polymers, with the catiomcs being generally prefe ⁇ ed
  • crosslinked noniomc polyacrylate polymers and crosslinked cationic polyacrylate polymers are those described in U S Patent No 5,100,660, to Hawe et al, issued March 31, 1992, U S Patent No 4,849,484, to Heard, issued July 18, 1989, U S Patent No 4,835,206, to Fa ⁇ ar et al, issued May 30, 1989, U S Patent No 4,628,078 to Glover et al issued December 9, 1986, U S Patent No 4,599,379 to Flesher et al issued July 8, 1986, and EP 228,868, to Fa ⁇ ar et al, published July 15, 1987 c) Polyacrylamide Polymers
  • compositions of the present invention can optionally comprise polyacrylamide polymers, especially noniomc polyacrylamide polymers including substituted branched or unbranched polymers. Most prefe ⁇ ed among these polyacrylamide polymers is the nomonic polymer given the CTFA designation polyacrylamide and lsoparaffin and laureth-7, available under the Tradename Sepigel 305 from Seppic Corporation (Fairfield, NJ)
  • polyacrylamide polymers useful herein include multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids
  • Commercially available examples of these multi-block copolymers include Hypan SR150H, SS500V, SS500W, SSSA100H, from Lipo Chemicals, Inc., (Patterson, NJ).
  • Polysaccha ⁇ des include Hypan SR150H, SS500V, SS500W, SSSA100H, from Lipo Chemicals, Inc., (Patterson, NJ).
  • Polysaccha ⁇ des refer to gelling agents that contam a backbone of repeatmg sugar (I e , carbohydrate) units
  • Nonlimitmg examples of polysaccha ⁇ de gelling agents include those selected from the group consisting of cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystallme cellulose, sodium cellulose sulfate, and mixtures thereof
  • the alkyl- substituted celluloses In these polymers, the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C ⁇ 0 -C 30 straight cham
  • these polymers are ethers of C ⁇ o-C 30 straight or branched chain alcohols with hydroxyalkylcelluloses
  • alkyl groups useful herem include those selected from the group consistmg of stearyl, isostearyl, lauryl, mynstyl, cetyl, lsocetyl, cocoyl (I e alkyl groups derived from the alcohols of coconut oil), palmityl, oleyl, lmoleyl, hnolenyl, ⁇ cinoleyl, behenyl, and mixtures thereof
  • Prefe ⁇ ed among the alkyl hydroxyalkyl cellulose ethers is the material given the CTFA designation cetyl hydroxyethylcellulose, which is the ether of cetyl alcohol and hydroxyethylcellulose This material is sold under the tradename Natrosol® CS Plus from Aqualon Corporation (Wilmington, DE).
  • polysaccha ⁇ des include scleroglucans comprising a linear chain of (1-3) linked glucose units with a (1-6) linked glucose every three units, a commercially available example of which is ClearogelTM CS11 from Michel Mercier Products Inc (Mountainside, NJ). e) Gums
  • gelling agent gums include materials selected from the group consisting of acacia, agar, algin, algmic acid, ammonium alginate, amylopectm, calcium algmate, calcium ca ⁇ ageenan, carnitine, ca ⁇ ageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimomum chloride, hecto ⁇ te, hyaluroimc acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium algmate, potassium canageenan, propylene glycol algmate, sclerotium gum, sodium carboyxmethyl dextran, sodium ca ⁇ ageenan, tragacanth gum, xanthan gum, and mixture
  • compositions of the present invention include a thickening agent selected from the group consisting of carboxyhc acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof, more preferably selected from the group consisting of carboxyhc acid polymers, polyacrylamide polymers, and mixtures thereof Composition Preparation
  • compositions of the present invention are generally prepared by conventional methods such as are known m the art of making topical compositions Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like Methods for Regulating Keratinous Tissue Condition
  • compositions of the present mvention are useful for regulating a number of mammalian keratmous tissue conditions
  • Such regulation of keratinous tissue conditions mcludes prophylactic and therapeutic regulation More specifically, such regulating methods are directed to, but are not limited to, thickening keratinous tissue (1 e , building the epidermis and/or derrms and/or subcutaneous layers of the skin and where applicable the keratinous layers of the nail and hair shaft) and preventmg, retarding, and/or treating atrophy of mammalian skm, preventing, retarding, and/or treating the appearance of dark, under- eye circles and or puffy eyes, preventmg, retardmg, and/or treatmg sallowness of mammalian skm, preventing and/or retarding tanning of mammalian skm, desquamating, exfoliating, and or increasmg turnover in mammalian skin, reducing the size of pores in mammalian skm, regulating oily
  • Regulating keratinous tissue condition involves topically applying to the keratinous tissue a safe and effective amount of a composition of the present invention
  • the amount of the composition that is applied, the frequency of application and the period of use will vary widely depending upon the level of phytosterol and/or other components of a given composition and the level of regulation desired, e g , m light of the level of keratinous tissue damage present or expected to occur
  • the composition is chronically applied to the skm
  • chrome topical application is meant continued topical application of the composition over an extended period du ⁇ ng the subject's lifetime, preferably for a period of at least about one week, more preferably for a period of at least about one month, even more preferably for at least about three months, even more preferably for at least about six months, and more preferably still for at least about one year While benefits are obtainable after various maximum periods of use (e g , five, ten or twenty years), it is prefe ⁇ ed that chronic applications continue throughout the subject's lifetime Typically applications would be on the order of about once per day over such extended periods, however application rates can vary from about once per week up to about three times per day or more
  • a wide range of quantities of the compositions of the present invention can be employed to provide a skm appearance and/or feel benefit Quantities of the present compositions, which are typically applied per application, are, in mg skm, from about 0.1 v g/ct
  • Regulating keratinous tissue condition is preferably practiced by applying a composition m the form of a skin lotion, clear lotion, milky lotion, cream, gel, foam, ointment, paste, emulsion, spray, conditioner, tonic, cosmetic, lipstick, foundation, nail polish, after-shave, or the like which is intended to be left on the skm or other keratinous tissue for some esthetic, prophylactic, therapeutic or other benefit (i.e , a "leave-on" composition)
  • the composition to the keratinous tissue e.g , skm
  • it is preferably left on for a period of at least about 15 mmutes, more preferably at least about 30 mmutes, even more preferably at least about 1 hour, most preferably for at least several hours, e.g , up to about 12 hours
  • Any part of the external portion of the face, hair, and or nails can be treated, e g , face, lips, under-eye area, eyelids, scalp
  • Another approach to ensure a continuous exposure of the keratinous tissue to at least a minimum level of the phytosterol is to apply the compound by use of a patch applied, e.g , to the face.
  • a patch applied e.g , to the face.
  • the patch can be occlusive, semi-occlusive or non- occlusive
  • the phytosterol composition can be contained within the patch or be applied to the skm prior to application of the patch.
  • the patch can also include additional actives such as chemical imtiators for exothermic reactions such as those described in PCT application WO 9701313 to Burkett et al.
  • the patch is preferably left on the keratinous tissue for a period of at least about 5 minutes, more preferably at least about 15 minutes, more preferably still at least about 30 minutes, even more preferably at least about 1 hour, most preferably at night as a form of night therapy
  • a skm cream is prepared by conventional methods from the following components.
  • Blend the A phase components with a suitable mixer e.g , Tekmar model RW20DZM
  • a suitable mixer e.g , Tekmar model RW20DZM
  • heating while stimng to a temperature of 70-80°C blend the B phase components with a suitable mixer and heat with mixing to melt the components.
  • blend the C phase components and mill to obtam an acceptably smooth mixture e g , using a Tekmar T50 Mill
  • composition to a subject's intrinsically aged, sagging or photodamaged facial skin at the rate of 2 mg composition/cm ⁇ skin once or twice daily for a period of at least 3-6 months to increase skin thickness and dimmish skm sagging
  • Example 2 An emulsion is prepared by conventional methods from the following components:
  • Example 3 A skin cream is prepared by conventional methods from the following components.
  • Blend the A phase components with a suitable mixer e.g., Tekmar model RW20DZM
  • a suitable mixer e.g., Tekmar model RW20DZM
  • blend the C phase components and mill to obtain an acceptably smooth mixture e.g., using a Tekmar T50 Mill.
  • composition to a subject's intrinsically aged, sagging or photodamaged facial sk at the rate of 2 mg skin once or twice daily for a period of at least 3-6 months to mcrease skm thickness and diminish skm sagging
  • Example 4 A skin cream is prepared by conventional methods from the following components.
  • Blend the A phase components with a suitable mixer e g , Tekmar model RW20DZM.
  • Blend the B phase components into the A phase with a suitable mixer Separately, blend the C phase components until they are uniform Add the C phase mixture to the A/B phase mixture, mix until umform and emulsified, and then mill to obtain an acceptably smooth mixture (e g , using a Tekmar T50 Mill).
  • composition to a subject's intrinsically aged, sagging, or photodamaged facial skm at the rate of 2 mg skin once or twice daily for a period of at least 3-6 months to increase skm thickness and dimmish skin saggmg
  • An alternative skin cream havmg reduced retinol levels can be prepared in the same manner from the above components wherein the retinol is added in an amount of 0.025% (0 25% of 10% retinol in soybean oil), quo sme to 100% with water, the amounts of the other components being as shown
  • a skin cream is prepared by conventional methods from the following components
  • composition to a subject's intrinsically aged, sagging, or photodamaged facial skm at the rate of 2 mg composition crcr skin once or twice daily for a period of at least 3-6 months to increase skin thickness and dimmish skin sagging.
  • Example 6 A skin cream is prepared by conventional methods from the following components.
  • compositions to a subject's skm compromised by events like acne, scratch, msect bite, sunburn, etc., at the rate of 10 mg skm 2-4 times daily for a period of at least 1-2 weeks to prevent development of post- inflammatory hyperpigmentation.
  • Example 7 A skm cream is prepared by conventional methods from the following components.
  • Blend the A phase components with a suitable mixer e g , Tekmar model RW20DZM
  • a suitable mixer e g , Tekmar model RW20DZM
  • heatmg while sti ⁇ mg to a temperature of 70-80°C Separately, blend the B phase components with a suitable mixer and heat with mixing to melt the components Separately, blend the C phase components and mill to obtain an acceptably smooth mixture (e g , using a Tekmar T50 Mill)
  • Example 8 An emulsion is prepared by conventional methods from the following components:
  • sihcone phase m a separate suitable vessel by adding and sti ⁇ mg together the sihcone fluids and the campesterol
  • Example 9 A skm cream is prepared by conventional methods from the following components.
  • Blend the A phase components with a suitable mixer e g , Tekmar model RW20DZM
  • a suitable mixer e g , Tekmar model RW20DZM
  • mixing at about 70-80°C to melt the components
  • blend the C phase components and mill to obtain an acceptably smooth mixture e g , using a Tekmar T50 Mill
  • Add the C phase mixture to the above mixture and mix Remove the combmation from the bath, with contmued stimng, once the temperature reaches about 45°C. Add the dimethicone and mix.
  • composition to a subject's intrinsically aged, saggmg or photodamaged facial skm at the rate of 2 mg skin once or twice daily for a period of at least 3-6 months to increase skm thickness and dimmish skm saggmg.
  • Examples 10-12 A skm cream is prepared by conventional methods from the following components.
  • Blend the A phase components with a suitable mixer e.g , Tekmar model RW20DZM.
  • Blend the B phase components into the A phase with a suitable mixer Separately, blend the C phase components until they are uniform Add the C phase mixture to the A B phase mixture, mix until uniform and emulsified, and then mill to obtain an acceptably smooth mixture (e g., using a Tekmar T50 Mill).
  • Oil-in-water emulsions are prepared from the following ingredients using conventional formulating techniques.
  • phase A ingredients in a suitable size vessel and heat to 70-75°C.
  • phase B ingredients and heat to 70-75°C.
  • phase C add phase B to phase A while continuing to mix.
  • phase C add phase C to the batch mixture of phases A B while continuing to mix.
  • the phase C component allows neutralization of the mixture
  • mix Phase D until umform and then add to the batch mixture of phases A/B/C while contmumg to mix Cool to 50°C.
  • Mix Phase E mgredients until uniform and then add to the batch mixture of phases A-D while continuing to mix.
  • Phase F ingredient to the batch mixmre of A-E and contmue to cool to about 35°C Mixing is contmued until the resulting batch mixture is uniform
  • composition to a subject's intrinsically aged, sallow, or photodamaged facial skm at the rate of 2 mg skin once or twice daily for a period of at least 3-6 months to increase skm thickness and dimmish skm sallowness
  • Examples 17-18 The emulsions are prepared from the following ingredients using conventional formulating techniques.
  • composition to a subject's sun exposed skin at the rate of 2 mg skm prior to and durmg sun exposure to prevent and/or retard tanmng, sallowness, and other signs of prematured agmg in skm.
  • compositions shown below can be prepared by any conventional method known in the art

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2000/012155 1999-05-17 2000-05-04 Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions WO2000069404A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP00928813A EP1181006A1 (en) 1999-05-17 2000-05-04 Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions
CA002373158A CA2373158A1 (en) 1999-05-17 2000-05-04 Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions
AU46992/00A AU771934B2 (en) 1999-05-17 2000-05-04 Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions
BR0010619-4A BR0010619A (pt) 1999-05-17 2000-05-04 Processos para regularizarem e/ou tratarem a condição de tecido ceratinoso e/ou da pele de mamìferos e composições adequadas para o uso na regularização da condição de tecido ceratinoso e/ou da pele de mamìferos
JP2000617863A JP2002544217A (ja) 1999-05-17 2000-05-04 フィトステロール組成物の局所適用による哺乳動物ケラチン組織の状態の調整方法
MXPA01011801A MXPA01011801A (es) 1999-05-17 2000-05-04 Metodos para regular la condicion de tejido queratinoso de mamifero mediante la aplicacion topica de composiciones de fitoesterol.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13439799P 1999-05-17 1999-05-17
US60/134,397 1999-05-17
US43943899A 1999-11-15 1999-11-15
US09/439,438 1999-11-15

Publications (1)

Publication Number Publication Date
WO2000069404A1 true WO2000069404A1 (en) 2000-11-23

Family

ID=26832289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012155 WO2000069404A1 (en) 1999-05-17 2000-05-04 Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions

Country Status (11)

Country Link
US (2) US20020098218A1 (zh)
EP (1) EP1181006A1 (zh)
JP (1) JP2002544217A (zh)
KR (1) KR100455470B1 (zh)
CN (1) CN1177580C (zh)
AU (1) AU771934B2 (zh)
BR (1) BR0010619A (zh)
CA (1) CA2373158A1 (zh)
CZ (1) CZ20014004A3 (zh)
MX (1) MXPA01011801A (zh)
WO (1) WO2000069404A1 (zh)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087257A1 (de) * 2000-05-18 2001-11-22 Ipr-Institute For Pharmaceutical Research Ag Kosmetische zubereitung zur topischen anwendung bei der behandlung von cellulite
WO2002045728A1 (de) * 2000-12-06 2002-06-13 Cognis France S.A. Kosmetische und/oder dermopharmazeutische zubereitungen enthaltend extrakte aus den blättern der pflanze argania spinosa
KR20020063987A (ko) * 2001-01-31 2002-08-07 나드리화장품주식회사 피부자극완화효과를 가진 화장료 조성물
WO2003041675A2 (de) * 2001-11-12 2003-05-22 Skinlab Gmbh Verwendung von sterolen und von deren derivaten in kosmetischen und dermatologischen zubereitungen zum zwecke der uva-protektion
KR20030061985A (ko) * 2002-01-14 2003-07-23 (주)대덕바이오 스티그마스테롤을 함유하는 미백용 조성물
WO2004006882A1 (de) * 2002-07-13 2004-01-22 Merz Pharma Gmbh & Co. Kgaa Vesikelbildende reinigungszubereitung mit hohem wirkstoffanteil, verfahren zu ihrer herstellung sowie ihre verwendung
EP1407760A1 (de) * 2002-10-08 2004-04-14 Cognis France S.A. Verfahren zum Schutz der Haut gegen Alterung
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
DE10301834A1 (de) * 2003-01-20 2004-07-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit verbesserter Perlglanzoptik
DE10301836A1 (de) * 2003-01-20 2004-07-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit Perlglanzoptik
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
DE10340417C5 (de) * 2003-09-02 2011-05-05 Sebapharma Gmbh & Co. Kg Kosmetische oder dermatologische Zubereitung mit Phytosterolen in Form einer W/O-Emulsion
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
WO2013083431A1 (en) * 2011-12-06 2013-06-13 Unilever Plc Skin anti-ageing composition
EP3845232A4 (en) * 2018-08-30 2022-05-04 Daisankasei Co., Ltd. NOVEL USE OF PHYTOSTENON

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4516202B2 (ja) * 2000-11-01 2010-08-04 株式会社ファンケル 化粧料
US7713472B2 (en) * 2001-01-12 2010-05-11 Board Of Regents, The University Of Texas System Antiseptic derivatives with broad spectrum antimicrobial activity for the impregnation of surfaces
US7368122B1 (en) * 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US20040175347A1 (en) * 2003-03-04 2004-09-09 The Procter & Gamble Company Regulation of mammalian keratinous tissue using hexamidine compositions
EP1635779B1 (en) * 2003-04-24 2009-12-09 L'oreal Cosmetic peeling method using urea
US20040219177A1 (en) * 2003-04-29 2004-11-04 Jacobs Randy J. Depleted skin barrier replenishing skin creams composition and method of application
DE10352368A1 (de) * 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von Licochalkon A zur Behandlung von Insektenstichen
WO2005072281A2 (en) * 2004-01-20 2005-08-11 Board Of Regents, The University Of Texas System Methods for coating and impregnating medical devices with antiseptic compositions
EP1671679B1 (de) * 2004-12-06 2011-06-22 Sebapharma GmbH & Co. KG Kosmetische oder dermatologische Zubereitung mit Phytosterolen in Form einer W/O-Emulsion
CN100361663C (zh) * 2006-03-06 2008-01-16 李海涛 一种含有植物甾醇的凝胶剂及其制备方法
CN101578086A (zh) * 2007-01-16 2009-11-11 宝洁公司 化妆品组合物
EP2055351B1 (en) * 2007-10-29 2016-05-25 The Procter and Gamble Company Compositions with durable pearlescent aesthetics
WO2009107073A1 (en) * 2008-02-29 2009-09-03 The Procter & Gamble Company Methods, kits and method of marketing for increasing hair diameter and delivering additional benefits
WO2013025893A1 (en) * 2011-08-16 2013-02-21 The Gillette Company Personal care compositions comprising an anti-irritation agent
EP2638933A1 (de) * 2012-03-15 2013-09-18 Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & Co. KG Kosmetikprodukte für die Altershaut
AU2014392629B2 (en) 2014-04-30 2021-04-01 Kimberly-Clark Worldwide, Inc. Use of Undaria extract to reduce signs of skin aging
BR112016023653B1 (pt) 2014-04-30 2020-12-08 Kimberly-Clark Worldwide, Inc composição tópica
BR112016022734B1 (pt) 2014-04-30 2020-12-01 Kimberly-Clark Worldwide, Inc. método para redução do estresse oxidativo das células, método para redução da apoptose de células induzida pelo estresse oxidativo e método para redução do fotodano das células
BR112016023890B1 (pt) 2014-04-30 2020-12-01 Kimberly-Clark Worldwide, Inc métodos para reduzir sinais de envelhecimento da pele, para aumentar a adipogênese da face e do corpo e para aumentar a lipogênese da face e do corpo
FR3030231B1 (fr) * 2014-12-23 2018-08-24 L'oreal Utilisation d'un ester d'acide gras pour matifier la peau et composition comprenant cet ester
EP3090781A1 (en) * 2015-05-08 2016-11-09 Susanne Kaufmann Anti-age composition with plant extracts
JP6419661B2 (ja) * 2015-08-22 2018-11-07 クローダジャパン株式会社 皮膚外用剤組成物および該皮膚外用剤組成物を含有する皮膚外用剤
JP6353939B1 (ja) * 2017-02-15 2018-07-04 横関油脂工業株式会社 油状組成物、その製法、油性基剤および皮膚外用剤
JP7546341B2 (ja) * 2018-07-24 2024-09-06 ロート製薬株式会社 コレステロール及び／又はフィトステロールを含有する外用組成物
CN109010123A (zh) * 2018-09-21 2018-12-18 珠海伊斯佳科技股份有限公司 一种改善头皮生理状态的组合物及其制备方法和应用
EP4003282B1 (en) 2019-07-29 2023-08-30 Echo Pharmaceuticals B.V. Treatment of aging or uv-damaged skin
US20210196594A1 (en) * 2019-12-26 2021-07-01 L'oreal Compositions and methods for eyelashes

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57131716A (en) * 1981-01-28 1982-08-14 Hiroshi Sekimoto Cosmetic for exclusive use to plantar skin
SU1138162A1 (ru) * 1983-04-28 1985-02-07 Ленинградская Ордена Ленина Лесотехническая Академия Им.С.М.Кирова Крем дл губ
JPS60120805A (ja) * 1983-11-30 1985-06-28 Akira Kitano 皮膚化粧料
US4604281A (en) * 1983-03-21 1986-08-05 Charles Of The Ritz Group Ltd. Cosmetic and skin treatment compositions containing acetylated sterols
JPH0196109A (ja) * 1987-10-06 1989-04-14 Lion Corp 美白化粧料
JPH06128137A (ja) * 1992-10-13 1994-05-10 Pola Chem Ind Inc 化粧料
US5310556A (en) * 1993-06-09 1994-05-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition
EP0716848A2 (en) * 1994-12-02 1996-06-19 Unilever Plc Cosmetic emulsions with a deposition triggering lipid system
RU2069557C1 (ru) * 1992-01-31 1996-11-27 ТОО "Фитолон" Крем для кожи
WO1999018913A2 (de) * 1997-10-10 1999-04-22 Cognis Deutschland Gmbh Verwendung von sterolestern als rückfettungsmittel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391732A (en) * 1975-06-06 1983-07-05 Henkel Corporation Phytosterol blends
JP3302525B2 (ja) * 1995-04-13 2002-07-15 花王株式会社 皮膚外用剤

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57131716A (en) * 1981-01-28 1982-08-14 Hiroshi Sekimoto Cosmetic for exclusive use to plantar skin
US4604281A (en) * 1983-03-21 1986-08-05 Charles Of The Ritz Group Ltd. Cosmetic and skin treatment compositions containing acetylated sterols
SU1138162A1 (ru) * 1983-04-28 1985-02-07 Ленинградская Ордена Ленина Лесотехническая Академия Им.С.М.Кирова Крем дл губ
JPS60120805A (ja) * 1983-11-30 1985-06-28 Akira Kitano 皮膚化粧料
JPH0196109A (ja) * 1987-10-06 1989-04-14 Lion Corp 美白化粧料
RU2069557C1 (ru) * 1992-01-31 1996-11-27 ТОО "Фитолон" Крем для кожи
JPH06128137A (ja) * 1992-10-13 1994-05-10 Pola Chem Ind Inc 化粧料
US5310556A (en) * 1993-06-09 1994-05-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition
EP0716848A2 (en) * 1994-12-02 1996-06-19 Unilever Plc Cosmetic emulsions with a deposition triggering lipid system
WO1999018913A2 (de) * 1997-10-10 1999-04-22 Cognis Deutschland Gmbh Verwendung von sterolestern als rückfettungsmittel

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198534, Derwent World Patents Index; AN 1985-208922, XP002146585 *
DATABASE WPI Week 198921, Derwent World Patents Index; AN 1989-155036, XP002146584 *
DATABASE WPI Week 199729, Derwent World Patents Index; AN 197-318112, XP002146583 *
PATENT ABSTRACTS OF JAPAN vol. 18, no. 427 (C - 1235) 10 August 1994 (1994-08-10) *
PATENT ABSTRACTS OF JAPAN vol. 6, no. 227 (C - 134) 12 November 1982 (1982-11-12) *
PATENT ABSTRACTS OF JAPAN vol. 9, no. 271 (C - 311) 29 October 1985 (1985-10-29) *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
WO2001087257A1 (de) * 2000-05-18 2001-11-22 Ipr-Institute For Pharmaceutical Research Ag Kosmetische zubereitung zur topischen anwendung bei der behandlung von cellulite
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US7105184B2 (en) 2000-12-06 2006-09-12 Cognis France S.A. Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant Argania spinosa
WO2002045728A1 (de) * 2000-12-06 2002-06-13 Cognis France S.A. Kosmetische und/oder dermopharmazeutische zubereitungen enthaltend extrakte aus den blättern der pflanze argania spinosa
KR20020063987A (ko) * 2001-01-31 2002-08-07 나드리화장품주식회사 피부자극완화효과를 가진 화장료 조성물
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
WO2003041675A3 (de) * 2001-11-12 2003-09-04 Skinlab Gmbh Verwendung von sterolen und von deren derivaten in kosmetischen und dermatologischen zubereitungen zum zwecke der uva-protektion
WO2003041675A2 (de) * 2001-11-12 2003-05-22 Skinlab Gmbh Verwendung von sterolen und von deren derivaten in kosmetischen und dermatologischen zubereitungen zum zwecke der uva-protektion
KR20030061985A (ko) * 2002-01-14 2003-07-23 (주)대덕바이오 스티그마스테롤을 함유하는 미백용 조성물
WO2004006882A1 (de) * 2002-07-13 2004-01-22 Merz Pharma Gmbh & Co. Kgaa Vesikelbildende reinigungszubereitung mit hohem wirkstoffanteil, verfahren zu ihrer herstellung sowie ihre verwendung
WO2004054532A1 (de) * 2002-10-08 2004-07-01 Cognis France S.A. Verfahren zum schutz der haut gegen alterung
EP1407760A1 (de) * 2002-10-08 2004-04-14 Cognis France S.A. Verfahren zum Schutz der Haut gegen Alterung
DE10301834A1 (de) * 2003-01-20 2004-07-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit verbesserter Perlglanzoptik
DE10301836A1 (de) * 2003-01-20 2004-07-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit Perlglanzoptik
US7820150B2 (en) 2003-01-20 2010-10-26 Beiersdorf Ag Cosmetic or dermatological formulations of improved pearlescence
DE10340417C5 (de) * 2003-09-02 2011-05-05 Sebapharma Gmbh & Co. Kg Kosmetische oder dermatologische Zubereitung mit Phytosterolen in Form einer W/O-Emulsion
WO2013083431A1 (en) * 2011-12-06 2013-06-13 Unilever Plc Skin anti-ageing composition
AU2012348700B2 (en) * 2011-12-06 2015-08-27 Unilever Plc Skin anti-ageing composition
US10406091B2 (en) 2011-12-06 2019-09-10 Conopco, Inc. Skin anti-ageing composition
EP3845232A4 (en) * 2018-08-30 2022-05-04 Daisankasei Co., Ltd. NOVEL USE OF PHYTOSTENON

Also Published As

Publication number Publication date
CN1177580C (zh) 2004-12-01
CN1351487A (zh) 2002-05-29
US20020098218A1 (en) 2002-07-25
CA2373158A1 (en) 2000-11-23
MXPA01011801A (es) 2002-04-24
BR0010619A (pt) 2002-02-19
KR20020011987A (ko) 2002-02-09
AU771934B2 (en) 2004-04-08
CZ20014004A3 (cs) 2002-05-15
EP1181006A1 (en) 2002-02-27
JP2002544217A (ja) 2002-12-24
AU4699200A (en) 2000-12-05
KR100455470B1 (ko) 2004-11-06
US20040132699A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU771934B2 (en) Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions
US7235249B2 (en) Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions
AU2004218346B2 (en) Regulation of mammalian keratinous tissue using hexamidine compositions
AU770510B2 (en) Skin care compositions containing combination of skin care actives
EP2105123B1 (en) Skin care compositions containing a sugar amine and a vitamin B3 compound
AU4470000A (en) Methods for regulating the condition of mammalian keratinous tissue
MXPA01010631A (es) Composiciones para el cuidado de la piel que contienen una combinacion de ingredientes activos para el cuidado de la piel.
EP1178776A1 (en) Methods of regulating the condition of mammalian keratinous tissue
WO2000069406A1 (en) Methods of regulating the condition of mammalian keratinous tissue
WO2000069407A1 (en) Methods for upregulating and/or modulating kgf production and increasing receptivity of keratinocytes to kgf
WO2000069409A1 (en) Methods for upregulating and/or modulating kgf production and increasing receptivity of keratinocytes to kgf

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807703.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2373158

Country of ref document: CA

Ref document number: 2373158

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-4004

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2000 617863

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011801

Country of ref document: MX

Ref document number: 1020017014627

Country of ref document: KR

Ref document number: 46992/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000928813

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017014627

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000928813

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-4004

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 46992/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020017014627

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000928813

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-4004

Country of ref document: CZ